IP Library Granted Patent US 11,090,297
Granted Patent B2
US 11,090,297 · App. 16/438,508 · Granted Aug 17, 2021

Pridopidine for treating huntington's disease

Inventors: Merav Bassan (Netanya, IL); Esther Lukasiewicz Hagai (Tel Aviv, IL); Eli Eyal (Petah-Tikva, IL); Anna Kristina Sveinsdotter Teige Wickenberg (Lund, SE)
Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
A61K31/451A61K9/0053A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,297
App. No.
16/438,508
Granted
Aug 17, 2021
Kind
B2
Abstract

A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.

Claims (3)

1. A method of reducing impairment of functional capacity of a human patient afflicted with Huntington disease, comprising orally administering to the human patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof, in combination with at least one of compound 1 or compound 4, or pharmaceutically acceptable salt thereof:

thereby reducing impairment of functional capacity of the human patient.

2. The method of claim 1 , wherein the composition comprises pridopidine or a pharmaceutically acceptable salt thereof, with compound 1 and compound 4, or pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2019
From: BASSAN, MERAV; LUKASIEWICZ HAGAI, ESTHER; EYAL, ELI; SVEINSDOTTER TEIGE WICKENBERG, ANNA KRISTINA
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 049659/0558 →